Working… Menu
Trial record 1 of 1 for:    NCT02509286
Previous Study | Return to List | Next Study

Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus (ESOPEC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02509286
Recruitment Status : Recruiting
First Posted : July 28, 2015
Last Update Posted : August 7, 2018
Clinical Trials Unit Freiburg
CTC laboratories at University of Hamburg and University of Freiburg
ESOPEC reference pathology at the University of Freiburg
Universitätsklinikum Leipzig, Universitäres Krebszentrum (UCCL)
Information provided by (Responsible Party):
Prof. Dr. Jens Hoeppner, University Hospital Freiburg

Brief Summary:
The trial is designed to investigate differences in outcome of patients with esophageal adenocarcinoma and junctional adenocarcinoma treated with perioperative (neoadjuvant + adjuvant) chemotherapy (FLOT) plus surgical resection versus neoadjuvant chemoradiation (CROSS) plus surgical resection.

Condition or disease Intervention/treatment Phase
Esophageal Adenocarcinoma (UICC TNM7) Adenocarcinoma of the Esophagogastric Junction Drug: 5-Fluorouracil Drug: Leucovorin Drug: Oxaliplatin Drug: Docetaxel Drug: Carboplatin Drug: Paclitaxel Radiation: Neoadjuvant radiation Phase 3

Detailed Description:

According to the given evidence a survival benefit of perioperative chemotherapy (periCTX) over Neoadjuvant chemoradiation (neoCRT) for patients with Esophageal adenocarcinomas (EAC) has not been proven in any randomized controlled trials (RCT). Data supporting the value of periCTX have all been obtained in studies including mixed patient cohorts with EAC and gastric adenocarcinoma (GAC). Due to relevant differences of histologic subtype distribution, response to periCTX and survival rates between EAC and GAC there is a clear need to obtain evidence concerning the value of periCTX for EAC. As nowadays periCTX is extensively and successfully applied in clinical practice in patients with EAC there is an obvious need to obtain evidence from a multicentre RCT. Moreover a confirmation of the superior survival rates of the recent RCT on neoCRT should be obtained in a RCT conducted exclusively on EAC. Therefore, this prospective RCT with the primary objective of longterm patient survival comparing periCTX and neoCRT was designed.

Translational Projects:

Project 1+2: Circulating Tumor Cells as Biomarker in EAC CTC laboratories at University of Hamburg and University of Freiburg Project 3: Prognostic and predictive biomarkes in EAC University of Leipzig, UCCL

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 438 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus
Study Start Date : January 2016
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : June 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Perioperative Chemotherapy (FLOT):

The FLOT Arm consists of the FLOT protocol, which consists of 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel. Repetition every 2 weeks (d15, q2w). Four neoadjuvant cycles (8 weeks) prior to surgery and four adjuvant cycles (8 weeks) postoperatively are given.

Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization.

Drug: 5-Fluorouracil
2600 mg/m² (24 hours), d1 every two weeks;

Drug: Leucovorin
200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;

Drug: Oxaliplatin
85 mg/m² in 500 ml G5% over 2h, d1 every two weeks;

Drug: Docetaxel
50mg/m2 in 250 ml NaCl 0.9% over 1h, d1 every two weeks;

Active Comparator: Neoadjuvant Chemoradiation (CROSS):

The CROSS Arm consists of the CROSS protocol, which consists of neoadjuvant radiation therapy (41.4Gy / 23fractions) and concurrent chemotherapy with Carboplatin and Paclitaxel (5 weeks) prior to surgery.

Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization.

Drug: Carboplatin
Dose-dependant: 2mg/ml/min AUC in 500ml Glucose 5%, day 1, 8, 15, 22 and day 29.

Drug: Paclitaxel
50mg/m2 in 500ml NaCl 0.9% over 1 h, day 1, 8, 15, 22 and day 29;

Radiation: Neoadjuvant radiation
41.4Gy given in 23 fractions of 1.8Gy on days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31.

Primary Outcome Measures :
  1. Overall survival [ Time Frame: At end of trial- up to 3 years in follow up ]
    Overall survival will be calculated as time from start of study treatment to death due to any cause.

Secondary Outcome Measures :
  1. Progression free survival time (PFS) [ Time Frame: From randomisation up to 3 years in follow up ]
    PFS will be calculated as the time interval from randomisation to the first event of locoregional failure, metastatic progression or death.

  2. Site of failure: local, regional or distant Failure [ Time Frame: From time of surgery up to 3 years in follow up ]
  3. Recurrence free survival time [ Time Frame: From time of surgery up to 3 years in follow up ]
    RFS will be calculated in resected patients who achieved an R0 or R1 resection as the time interval from surgery to the date of first recurrence (local, regional or distant) or death, whatever comes first.

  4. Postsurgical Quality of Life [ Time Frame: From randomization up to 3 years in follow up ]
  5. Postoperative complications [ Time Frame: From time of surgery up to 90 days postoperatively ]
  6. Non-surgical site complications [ Time Frame: From time of surgery up to 90 days postoperatively ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Histologically verified adenocarcinoma of the esophagus according to the UICC definition (TNM7)
  • Pre-treatment stage cT1N+, M0 or cT2-4a, N0/+, M0
  • Age ≥18 years
  • No prior abdominal or thoracic radiotherapy
  • ECOG Performance status 0-2
  • Adequate cardiac function ( Patients with a cardiac history (e.g. myocardial infarction, heart failure, coronary artery disease) should have a cardiology review)
  • Adequate bone marrow function (WBC>3x10^9/l; Hb>9g/dl; platelets >100x10^9/l)
  • Adequate respiratory function. Symptomatic Patients should have pulmonary function tests with FEV1 >65% of predicted)
  • Adequate renal function (GFR >60ml/min)
  • Adequate liver function (serum bilirubin <1.5x Upper level of Normal (ULN); AST <2.5x ULN and ALT <3x ULN (ULN as per institutional standard)
  • written informed consent

Exclusion Criteria:

  • Tumors of squamous or other non-adenocarcinoma histology
  • Patients with advanced inoperable or metastatic esophageal adenocarcinoma
  • Stage cT1N0 and cT4b
  • Gastric carcinoma
  • Prior chemotherapy for cancer,
  • Clinically significant (i.e. active) cardiac disease (e.g. symptomatic coronary artery disease or myocardial infarction within last 12 months)
  • Clinical significant lung disease (FEV1 <65% of predicted)
  • Peripheral neuropathy Grade >1

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02509286

Layout table for location contacts
Contact: Jens Hoeppner, Professor +49 761 270-26970

Layout table for location information
Uniklinik RWTH Aachen Recruiting
Aachen, Germany
Principal Investigator: Ulf Peter Neumann, Professor         
Sub-Investigator: Christian Klink, PD Dr.         
Charité Berlin - Campus Benjamin Franklin (CBF) Recruiting
Berlin, Germany, 12203
Contact: Severin Daum, PD Dr.         
Principal Investigator: Severin Daum, PD Dr.         
Sub-Investigator: Hendrik Seeliger, PD Dr.         
Charité Berlin Campus Virchow-Klinikum (CVK) Recruiting
Berlin, Germany, 13353
Principal Investigator: Peter Thuß-Patience, PD Dr.         
Sub-Investigator: Matthias Biebl, PD Dr.         
Klinikum Dortmund gGmbH Recruiting
Dortmund, Germany, 44137
Contact: Maximilian Schmeding, Prof.         
Principal Investigator: Maximilian Schmeding, Prof.         
Sub-Investigator: Michael Heike, Prof.         
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden Recruiting
Dresden, Germany, 03107
Principal Investigator: Gunnar Folprecht, PD Dr.         
Sub-Investigator: Thilo Welsch, Prof.         
Universitätsklinikum Düsseldorf Recruiting
Düsseldorf, Germany
Principal Investigator: Matthias Schauer, PD Dr.         
Sub-Investigator: Wolfram Knoefel, Prof.         
Universitätsklinikum Erlangen Recruiting
Erlangen, Germany, 91054
Contact: Robert Grützmann, Prof.         
Principal Investigator: Robert Grützmann, Prof.         
Sub-Investigator: Dimitrios Raptis, Dr.         
Universitätsklinikum Frankfurt Recruiting
Frankfurt am Main, Germany, 60590
Contact: Detlef Imhoff, Dr.         
Principal Investigator: Detlef Imhoff, Dr.         
Sub-Investigator: Christian Keller, Dr.         
Universitätsklinikum Freiburg Recruiting
Freiburg, Germany
Principal Investigator: Jens Hoeppner, Professor         
Sub-Investigator: Ralph Fritsch, Dr.         
Universitätsmedizin Göttingen Recruiting
Göttingen, Germany, 37099
Principal Investigator: Jochen Gaedcke, PD Dr.         
Sub-Investigator: Alexander König, Dr.         
Universitätsklinikum Hamburg-Eppendorf Recruiting
Hamburg, Germany
Principal Investigator: Jakob R. Izbicki, Professor         
Sub-Investigator: Cordula Petersen, Professor         
Universitätsklinikum des Saarlandes Recruiting
Homburg, Germany, 66421
Contact: Frank Lammert, Prof.         
Principal Investigator: Frank Lammert, Prof.         
Sub-Investigator: Simone Zimmermann         
Universitätsklinikum Schleswig-Holstein, Campus Kiel Recruiting
Kiel, Germany
Principal Investigator: Thomas Becker, Professor         
Sub-Investigator: Benedikt Reichert, Dr.         
Uniklinik Köln Recruiting
Köln, Germany, 50937
Contact: Christiane Bruns, Prof.         
Principal Investigator: Christiane Bruns, Prof.         
Sub-Investigator: Thomas Zander, PD Dr.         
Sub-Investigator: Armin Tuchscherer, Dr.         
Universitätsklinikum Leipzig Recruiting
Leipzig, Germany
Principal Investigator: Ines Gockel, Professor         
Sub-Investigator: Orestis Lyros, Dr.         
Universitätsklinikum Schleswig-Holstein, Campus Lübeck Recruiting
Lübeck, Germany
Principal Investigator: Tobias Keck, Professor         
Sub-Investigator: Ralf Bouchard, Dr.         
Universitätsklinikum Magdeburg Recruiting
Magdeburg, Germany
Principal Investigator: Frank Benedix, Prof.         
Sub-Investigator: Marino Venerito, Dr.         
Universitätsmedizin Mainz Recruiting
Mainz, Germany
Principal Investigator: Peter Grimminger, PD Dr.         
Sub-Investigator: Stefan Heinrich, PD Dr.         
Johannes Wesling Klinikum Minden Recruiting
Minden, Germany, 32429
Contact: Kai Wille, Dr.         
Principal Investigator: Kai Wille, Dr.         
Sub-Investigator: Emil Sagynaliev, Dr.         
Klinikum der Universität München (LMU) Recruiting
München, Germany
Principal Investigator: Jens Werner, Professor         
Sub-Investigator: Martin Angele, Professor         
Universitätsklinikum Münster Recruiting
Münster, Germany
Principal Investigator: Andreas Pascher, Professor         
Sub-Investigator: Mike Laukötter, PD Dr.         
Ruppiner Kliniken GmbH Recruiting
Neuruppin, Germany, 16816
Contact: Andreas Loew, Dr.         
Principal Investigator: Andreas Loew, Dr.         
Sub-Investigator: Christoph Löschner, Dr.         
Sana Klinikum Offenbach GmbH Recruiting
Offenbach, Germany, 63069
Principal Investigator: Thomas Haist, Dr.         
Sub-Investigator: Mate Knabe, Dr.         
Universitätsklinikum Regensburg Recruiting
Regensburg, Germany, 93053
Contact: Felix Steger, Dr.         
Principal Investigator: Felix Steger, Dr.         
Sub-Investigator: Matthias Hautmann, Dr.         
Universitätsmedizin Rostock Recruiting
Rostock, Germany, 18059
Contact: Guido Hildebrandt, Prof.         
Principal Investigator: Guido Hildebrandt, Prof.         
Sub-Investigator: Marcella Szücs, Dr.         
Klinikum Stuttgart Recruiting
Stuttgart, Germany, 70174
Contact: Gerald Illerhaus, Professor         
Principal Investigator: Gerald Illerhaus, Gerald, Prof., Professor         
Sub-Investigator: Pascale Regincos, Dr.         
Robert-Bosch-Krankenhaus Stuttgart Recruiting
Stuttgart, Germany, 70376
Contact: Annette Steckkönig, Dr.         
Principal Investigator: Annette Steckkönig, Dr.         
Sub-Investigator: Anette Hoferer, Dr.         
Klinikum Mutterhaus Recruiting
Trier, Germany, 54290
Contact: Rolf Mahlberg, Dr.         
Principal Investigator: Rolf Mahlberg, Dr.         
Sub-Investigator: Stefan Heidel, Dr.         
Universitätsklinikum Würzburg Recruiting
Würzburg, Germany
Principal Investigator: Burkhard von Rahden, PD Dr.         
Principal Investigator: Volker Kunzmann, Professor         
Sponsors and Collaborators
University Hospital Freiburg
Clinical Trials Unit Freiburg
CTC laboratories at University of Hamburg and University of Freiburg
ESOPEC reference pathology at the University of Freiburg
Universitätsklinikum Leipzig, Universitäres Krebszentrum (UCCL)
Layout table for investigator information
Principal Investigator: Jens Hoeppner, Professor University Hospital Freiburg

Additional Information:
Layout table for additonal information
Responsible Party: Prof. Dr. Jens Hoeppner, Head of Upper GI Surgery Programm, University Hospital Freiburg Identifier: NCT02509286     History of Changes
Other Study ID Numbers: P000760
2015-001683-20 ( EudraCT Number )
DRKS00008008 ( Registry Identifier: DRKS )
First Posted: July 28, 2015    Key Record Dates
Last Update Posted: August 7, 2018
Last Verified: July 2018
Keywords provided by Prof. Dr. Jens Hoeppner, University Hospital Freiburg:
Esophageal neoplasms
gastro-esophageal junction neoplasms
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs